loading

Loading...

Case Study:
KOL Activity Network Mapping

The Problem


Our client manufactures an injectable prescription medicine used globally to treat more than 1 million adults with type 2 diabetes. The company later identified a new indication for the same drug to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease.

TLS had previously been retained to by the client to conduct an identification, profiling, mapping, and peer nomination project focusing on global and national key opinion leaders in diabetes.

As part of its global engagement strategy to support the new indication, our client now needed to identify global and national KOLs in the therapeutic areas of both diabetes and cardiology from ten countries. Further, they needed to pinpointing the intersection of diabetes and cardiology, and hone in on known and emerging KOLs whose collaborative activities spanned the two therapeutic specialties.

The Solution


(click to enlarge)

(click to enlarge)

For this project, TLS deployed its Activity Network Mapping solution. In light of the ever-increasing complexity of the healthcare marketplace, this solution offers cutting-edge, objective methods of identifying KOLs – as well as emerging stars in healthcare – by seeing how they intersect across thought leadership activities, disease states, and geographies.

To meet the specific needs of the client, TLS developed a three-step approach:

  1. Creation of an identification database comprised of hand-picked and prioritized global and national KOLs across the two specialties (diabetes and cardiology) and across multiple areas of activity.
  2. Development of professional impact network (PIN) maps linking the identified KOLs in diabetes and cardiology in each country through expert collaborations.
  3. Analysis of PIN maps to reveal newly identified KOLs in diabetes and cardiology with whom existing KOLs collaborate.

The Results


(click to enlarge)

(click to enlarge)

TLS identified 120 global KOLs in each of the two therapeutic areas, as well as 250 KOLs in each therapeutic area per country.

Deliverables included:
• Intra-country maps showing connections among KOLs within each country
• A global PIN map for all targeted geographies
• A visual analysis offering a variety of views showing connections among countries at both the individual KOL and country level
• Details on the identified KOLs’ clinical and academic affiliations as well as collaborative activities
• Profiles for internal stakeholders and engagement planners to reference when matching KOLs to key company activities.

In 2017, the drug was approved by the FDA to both treat type 2 diabetes and reduce the risk of major adverse cardiovascular events.



Contact:
Brian Castle, Sr. Director of Marketing & Strategy
919-360-9690
Email

Contact Us
Name:*
Enter your E-mail:*
Message